Skip to main content

Multiple Sclerosis Topic Center

News
03/26/2025
Grace Taylor, MS, MA
Chronic autoimmune conditions are emerging as a major, underrecognized burden on employers, driving up health care costs and disability claims across the US workforce.
Chronic autoimmune conditions are emerging as a major, underrecognized burden on employers, driving up health care costs and disability claims across the US workforce.
Chronic autoimmune conditions...
03/26/2025
First Report Managed Care
Conference Coverage
03/13/2025
Juliet Gallagher
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
News
03/12/2025
Grace Taylor, MS, MA
Commonly used medications for multiple sclerosis-related fatigue offer minimal clinical benefit and are more likely to cause treatment discontinuation due to side effects, according to a systematic review and meta-analysis published in...
Commonly used medications for multiple sclerosis-related fatigue offer minimal clinical benefit and are more likely to cause treatment discontinuation due to side effects, according to a systematic review and meta-analysis published in...
Commonly used medications for...
03/12/2025
First Report Managed Care
Conference Coverage
03/04/2025
Hannah Musick
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
03/04/2025
Hannah Musick
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
02/27/2025
Grace Taylor, MS, MA
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the...
02/27/2025
First Report Managed Care
Conference Coverage
02/27/2025
Grace Taylor, MS, MA
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s...
02/27/2025
First Report Managed Care
News
02/10/2025
Lisa Kuhns, PhD, MD
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple...
02/10/2025
First Report Managed Care
News
01/13/2025
Juliet Gallagher
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in...
01/13/2025
First Report Managed Care
News
12/19/2024
Jolynn Tumolo
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset...
12/19/2024
First Report Managed Care
Industry Insights